A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)
Latest Information Update: 16 Dec 2024
At a glance
- Drugs Retatrutide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms TRIUMPH-1
- Sponsors Eli Lilly and Company
Most Recent Events
- 06 Dec 2024 Planned number of patients changed from 2100 to 2300.
- 06 Dec 2024 Planned End Date changed from 13 May 2026 to 1 May 2026.
- 06 Dec 2024 Planned primary completion date changed from 15 Apr 2026 to 1 Apr 2026.